J&J(US:JNJ)2025-04-23 20:04Financial Performance - Total sales for the fiscal first quarter ended March 30, 2025, were $21,893 million, a 2.4% increase from $21,383 million in the same period of 2024[24]. - Gross profit margin decreased to 66.4% in Q1 2025 from 69.6% in Q1 2024, with cost of products sold rising to $7,357 million, representing 33.6% of sales[24]. - Net earnings for Q1 2025 were $10,999 million, a significant increase of 238.5% compared to $3,255 million in Q1 2024, resulting in a net earnings per share of $4.54[24]. - Comprehensive income for Q1 2025 was $11,000 million, compared to $5,014 million in Q1 2024, reflecting a strong performance despite foreign currency translation losses[25]. - Net earnings for the fiscal three months ended March 30, 2025, were $10,999 million, a significant increase from $3,255 million in the same period of 2024, representing a growth of approximately 237%[30]. Cash Flow and Dividends - Cash dividends paid in Q1 2025 were $2,989 million, with a dividend per share of $1.24, up from $2,869 million and $1.19 per share in Q1 2024[27]. - Net cash flows from operating activities increased to $4,174 million in Q1 2025, compared to $3,657 million in Q1 2024, reflecting a growth of about 14%[30]. - Cash and cash equivalents at the end of the period rose to $38,474 million, up from $25,473 million a year earlier, marking an increase of approximately 51%[31]. - The company reported a net cash from financing activities of $10,422 million in Q1 2025, a substantial increase from $546 million in Q1 2024[30]. Research and Development - Research and development expenses decreased to $3,225 million, accounting for 14.7% of sales, down from 16.6% in the previous year[24]. - Research and development expenses for Innovative Medicine were $2,548 million, down from $2,896 million in the previous year, indicating a focus on cost management[89]. Acquisitions and Investments - The company completed the acquisition of Intra-Cellular Therapies, Inc. for approximately $14.6 billion, funded through cash and debt issuance[94]. - The acquisition of Shockwave Medical Inc. was completed for $11.5 billion, with a fair value allocation of $14.4 billion primarily to amortizable intangible assets[98]. - The company completed the acquisition of Proteologix, Inc. for $0.8 billion, focusing on bispecific antibodies for immune-mediated diseases[97]. Legal and Regulatory Matters - The Company proposed a "prepackaged" Chapter 11 bankruptcy plan with a present value of approximately $6.475 billion payable over 25 years, addressing 99.75% of pending lawsuits related to its talc products[120]. - The Company has resolved 95% of mesothelioma lawsuits filed to date, with a total present value reserve of approximately $4.2 billion as of Q1 2025, which includes litigation defense and settlement costs[126]. - The Company continues to defend against approximately 35 remaining opioid cases in various state courts, with a settlement agreement for state and subdivision claims finalized for up to $5.0 billion[136]. Segment Performance - Sales in the Innovative Medicine segment for the fiscal first quarter of 2025 reached $5,678 million, a 17.9% increase from $4,814 million in the same quarter of 2024[81]. - Total Innovative Medicine sales increased by 6.3% in the U.S. to $8,092 million, while international sales decreased by 2.9% to $5,781 million, leading to a worldwide increase of 2.3% to $13,873 million[85]. - MedTech segment reported U.S. sales growth of 5.1% to $4,213 million, with international sales slightly declining by 0.2% to $3,807 million, resulting in a worldwide increase of 2.5% to $8,020 million[88]. Financial Position - The balance of retained earnings increased to $78,109 million as of March 30, 2025, up from $70,020 million at the end of Q1 2024[27]. - The company reported a significant other comprehensive income loss of $1 million in Q1 2025, contrasting with a gain of $1,759 million in Q1 2024[25]. - The company’s total intangible assets decreased to $36,755 million from $37,618 million, primarily due to amortization[42]. Tax and Liabilities - The worldwide effective income tax rate increased to 19.3% in the fiscal first quarter of 2025 from 12.4% in 2024, primarily due to higher income in the U.S.[68]. - The company had approximately $2.1 billion in liabilities from unrecognized tax benefits as of March 30, 2025[69]. Stock and Shareholder Actions - The company repurchased common stock worth $2,129 million during the quarter, compared to $1,475 million in the same quarter last year[27]. - The average shares outstanding for diluted earnings per share were 2,423.8 million in Q1 2025, slightly down from 2,430.1 million in Q1 2024[24].